<DOC>
	<DOCNO>NCT02713204</DOCNO>
	<brief_summary>The primary objective study compare efficacy intravitreal ( IVT ) -administered REGN910-3 compare intravitreal aflibercept injection ( IAI ) .</brief_summary>
	<brief_title>Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor therapY Neovascular Age Related Macular Degeneration : Evaluation fiXed Combination Intravitreal Injection</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<criteria>Key 1 . Men woman â‰¥50 year age active subfoveal CNV secondary AMD , include juxtafoveal lesion affect fovea evidence FA study eye assess central reading center 2 . BCVA ETDRS letter score 73 24 ( Snellen equivalent 20/40 20/320 ) study eye . 3 . Willing able comply clinic visit studyrelated procedure . 4 . Provide sign informed consent . Key 1 . Evidence CNV due cause AMD either eye 2 . Prior IVT antiVEGF study eye 3 . Evidence DME diabetic retinopathy ( defined 1 microaneurysm ) either eye diabetic patient 4 . Any history macular hole stage 2 study eye</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>